HIV TREATMENT ADHERENCE AND SUPPORT. Leonard Anang Sowah, MBChB, MPH, FACP Asst. Professor of Medicine University of Maryland Medical School
|
|
- Scott Norman
- 5 years ago
- Views:
Transcription
1 HIV TREATMENT ADHERENCE AND SUPPORT Leonard Anang Sowah, MBChB, MPH, FACP Asst. Professor of Medicine University of Maryland Medical School
2 The virus Virus uses host cell machinery to produce viral proteins and proviral RNA HIV virus produces more than a billion cells a day Reverse transcriptase enzyme has a very high error rate 1 every replication cycles 1 Mutant virus have characteristics that may be different from the wild-type virus HIV virus budding of from host cell 1 Coffin JM, Science 1995, 267; 5197: Image Credit -
3 Why is Adherence Important? 95% adherence required for viral suppression Resistance develops rapidly in setting of non-adherence HAART regimens in the setting of resistance more complex Risk of side-effects higher with patients with resistant virus Image credit -
4 Model of Adherence Patient Factors Disease Factors Treatment Compliance and Medication Adherence Social Cultural And Environmental Factors Treatment and Medication Factors
5 Development of Resistance HIV resistance develops when the virus replicates in non inhibiting drug concentrations Can happen in days for certain drugs may take longer with other drugs Viral resistance can affect a single drug or even multiple drugs of same class. Resistant virus may not be as healthy as wild-type virus Usually tends to reduce in relative numbers after the drug that selected for that mutation is withdrawn
6 Mechanisms of reducing resistance HAART (Highly Active Anti-Retroviral Therapy) Using drugs that rapidly reduce viral replication and achieve undetectable viremia Avoiding interactions that reduce drug concentrations or absorption of HIV drugs Using simple regimens and drugs that are well tolerated to ensure better adherence Providing supportive services for patients on ART therapy
7 The Disease Long asymptomatic stage in most individuals Development of drug resistance can occur due to poor compliance to HIV drugs Inherent variation and mutation rate of virus makes mono-therapy ineffective in the long term in most situations Disease manifestation makes it reasonable for people to doubt it is due to a single agent Inability to eliminate virus, thus need for lifelong treatment Mechanism of Infection
8 1. Denial of disease status 2. Lack of disclosure Patient factors 3. Poor insight and lack of education 1 about HIV 4. Lack of self efficacy 5. Depression 4 6. Anxiety disorder 7. Drug use and addiction 5 8. Mistrust of the provider and or health system 2 9. Spirituality Race/Ethnicity 1 Kalichman et al, J Gen Intern Med 1999; 14: Ickovics JR, Meisler AW, J Clin Epideniol. 1997; 50: Meredoth KL et al Health Edu & Behav 2001:28(1) Fairfield KM et al J Gen Intern Med. 1999; 14: Bangberg D. J Gen Intern Med. 1999; 14:
9 Patient Factors contd Reasons given for missing medication doses Kalichman et al, J Gen Intern Med 1999; 14:
10 Spirituality J Gen Intern Med 2006: 21 S62-68
11 Treatment and Medication Factors Regimen complexity 1 Pill burden Fitness of regimen into daily routine 1 Treatment related adverse events Route of drug administration Size of pill Storage of medications (refrigeration) Provider beliefs and expectations of patient 2 1 Gifford AL et al JAIDS (5) Paterson DL et al, Ann Intern Med 2000: 133; Image: wwwimage.cbsnews.com/.../01/24/image537878x.jpg
12 How to Prepare a Patient for ART! It is important to educate patients regarding the benefits and considerations regarding ART, and to address strategies to optimize adherence! On a case-by-case basis, ART may be deferred because of clinical and/or psychosocial factors, but therapy should be initiated as soon as possible.
13 When to Start ART! You have collected baseline labs! You have discussed with the patient the benefits of ART.! The patient is prepared to start therapy.! Genotype results are available.! What are your treatment options?
14 When to Start ART? Current DHHS Guideline! Antiretroviral therapy (ART) is recommended for all HIV-infected individuals, regardless of CD4 T lymphocyte cell count, to reduce the morbidity and mortality associated with HIV infection (AI).! ART is also recommended for HIV-infected individuals to prevent HIV transmission (AI).
15 Best time to Order Resistance Testing in virologic failure With virologic failure, obtain resistance testing while patient is on the failing regimen, or within four weeks of its discontinuation
16 Current FDA approved ART drugs
17 Treatment related Adverse effects Images:
18 1. Social support Socio-cultural 2. Spirituality 1 3. Employment situation 4. Stable housing 2, 3 5. Daily routine 6. Transportation preferences or availability 7. Child care and motherhood 8. Gender related issues 1 Ironson G; Ann of Behav Med. 2002; 24(1): Matinez J; J Natl Med Assoc. 2000; 92: Kiddler DP, Wolitsi RJ; Am J Public Health (12): Image:
19 Jan 42 yr old Caucasian female Active IV drug use Case 1 Heroin and cocaine last use yesterday HIV diagnosed 3 yrs prior to presentation Heterosexual in committed relationship with boyfriend of 2yrs Would like to get treatment for HIV Physical Exam Unremarkable except for scars from prior injection site abscess on left forearm
20 Labs Chem profile normal CBC, 11.8g/dl CD4 count 170 cells HIV Viral Load copies /ml Genotype revealed 2 minor Protease inhibitor mutations Referred for substance abuse counseling Counselor assessment patient willing to quit drug use, but does not feel ready Started on Bactrim and follow up in 4 weeks After 8 mths of some irregular follow up CD4 count dropped to 65 Started on Atripla after discussing adherence
21 Contd After patient was started on medications she was seen in 1mth and was not seen again for 4mths Attempts at reaching out were marginally successful Called patient several times, she promises to come to clinic but fails to show up What are you going to do?
22 Adherence Support by Mobile App
23 Follow up and goals of therapy! Improve quality of life! Reduce morbidity and mortality! Maximally inhibit HIV replication! Plasma HIV viral load lower than 20 c/ml! Prevent HIV transmission! Restore and preserve immunologic function
24 Summary Good adherence to HIV treatment is essential for healthy living in HIV patients The tools for success in ART therapy can be easily inculcated in patients The best outcomes are achieved when clients work well with their providers and support staff
Clinical Outcomes of Single Tablet vs. Multi-Tablet Antiretroviral Regimens in HIV-Infected Individuals
Clinical Outcomes of Single Tablet vs. Multi-Tablet Antiretroviral Regimens in HIV-Infected Individuals Abstract #18 IRB Approved Jeannie Ong, Pharm.D., AAHIVP PGY2 HIV Pharmacotherapy Resident University
More informationWhen to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationLow-Level Viremia in HIV
Mountain West AIDS Education and Training Center Low-Level Viremia in HIV Brian R. Wood, MD Medical Director, Mountain West AETC ECHO Telehealth Program Assistant Professor of Medicine, University of Washington
More informationSupervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis.
Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis. J.L. YOZVIAK 1, P. KOUVATSOS 2, R.E. DOERFLER 3, W.C. WOODWARD 3 1 Philadelphia College of Osteopathic
More informationAnti Retroviral Traitment (ARVs)
Anti Retroviral Traitment (ARVs) IEC material for People With Disabilities UPHLS - 2015 - Anti Retroviral Traitment Booklet Produced by AZ MEDIA No part of this publication may be reproduced without prior
More informationHIV and Public Health: the Basics
HIV and Public Health: the Basics Joy Zeh, RN, MS, Family Nurse Practitioner VCU HIV/AIDS Center HIV and Public Health: the Basics Epidemiology Related Infections and Co-Morbidities Spectrum of HIV Infection
More informationANTIRETROVIRAL THERAPY
ANTIRETROVIRAL THERAPY Editor s Note: Section III: Deciding When to Initiate ART is currently under revision due to recent data in favor of further expanding indications for antiretroviral therapy. What
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationDiagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know
Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know Carolyn K. Burr, EdD, RN Co-Clinical Director Deputy Director François-Xavier Bagnoud Center December 17 th, 2013
More informationINTEGRATING HIV INTO PRIMARY CARE
INTEGRATING HIV INTO PRIMARY CARE ADELERO ADEBAJO, MD, MPH, AAHIVS, FACP NO DISCLOSURE 1.2 million people in the United States are living with HIV infection and 1 in 5 are unaware of their infection.
More informationHIV Diagnostic Testing
In The name of God HIV Diagnostic Testing By : Dr. Shahzamani PhD of Medical virology Purpose of HIV Testing To identify asymptomatic individuals To diagnose HIV infection in those who practice high risk
More informationClinical Case. Prof.ssa Cristina Mussini
Clinical Case Prof.ssa Cristina Mussini Clinical history Male, born in Ivory Coast in 1968. HIV positive since dal 1998 Risk factor: heterosexual contacts He started antiretroviral therapy in 2001 with
More informationHIV Drug Resistance. Together, we can change the course of the HIV epidemic one woman at a time.
HIV Drug Resistance Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Resistance? HIV drugs are designed to keep the amount of HIV virus
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationAdherence Redux. Gordon Dickinson, MD Chief, ID, U Miami School of Medicine, and Co-Director, Special Immunology, Miami VA Med Center
Adherence Redux Gordon Dickinson, MD Chief, ID, U Miami School of Medicine, and Co-Director, Special Immunology, Miami VA Med Center To Be Human Is To Err People, on the whole, are not particularly adherent
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationClinical and Public Health Policy Implications of Findings that:
Clinical and Public Health Policy Implications of Findings that: Adherence to HIV Medications and Emotional/Physiological Coping with Stress are Independently Associated with Specific Five-Year Outcome
More informationImportance of Viral Suppression to Reduce HIV Transmission: Recent Evidence
Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine Viral suppression
More informationTreatment of HIV-1 in Adults and Adolescents: Part 2
Treatment of HIV-1 in Adults and Adolescents: Part 2 Heather E. Vezina, Pharm.D. University of Minnesota Laboratory Medicine & Pathology Experimental & Clinical Pharmacology wynnx004@umn.edu Management
More informationHIV/AIDS MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: HIV/AIDS MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN HIV/AIDS MEASURES GROUP: #159. HIV/AIDS: CD4+ Cell Count or CD4+ Percentage Performed #160. HIV/AIDS: Pneumocystis
More informationHIV infection and Primary Care. HIV Care in /30/2013. It s not the AIDS of 85. Stephen Raffanti MD MPH Vanderbilt University School of Medicine
HIV infection and Primary Care Stephen Raffanti MD MPH Vanderbilt University School of Medicine HIV Care in 2013 Chronic lifelong treatment with all the associated issues: medication tolerability medication
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationDiagnosis and Management of Acute HIV
Diagnosis and Management of Acute HIV A New HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV, this committee
More informationPrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute
PrEP for HIV Prevention Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the PrEP Guideline Raise awareness of PrEP among healthcare
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationMicropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ
www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons
More informationUse of a Multidisciplinary Care Model for Pregnant Women Living with HIV & Their Infants Sarah McBeth, MD MPH
Use of a Multidisciplinary Care Model for Pregnant Women Living with HIV & Their Infants Sarah McBeth, MD MPH University of Pittsburgh Medical Center Disclosures Presenter has no financial interests to
More informationClinical Management Guidelines 2012
Central American Course Monitoring and Evaluation for HIV/AIDS Policy and Program Management 1 2 3 4 Module 1 Unit 1 Clinical Management Guidelines 2012 National TB, HIV/AIDS & other STIs Programme Ministry
More informationMANITOBA HIV REPORT 2015
MANITOBA HIV REPORT 2015 The Manitoba HIV Program provides information, specialized care, treatment, and support to approximately 1,250 people living with HIV across the province. The Program has two Winnipeg-based
More informationObjectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.
1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships
More informationNatural history of HIV Infection
HIV in Primary Care Joint RCGP/BHIVA Multidisciplinary Conference Dr Ian Williams University College London Medical School Friday 25 January 2013, Royal College of General Practitioners, London HIV Treatment
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationAdherence. (Last update: June 2018) Together, we can change the course of the HIV epidemic one woman at a time.
Adherence (Last update: June 2018) Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject Strong Drugs to Fight HIV Advances in HIV treatment in past
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationDIAGNOSING AND MANAGING TREATMENT FAILURE. Dr. Jeremy Nel Department of Infectious Diseases Helen Joseph Hospital
DIAGNOSING AND MANAGING TREATMENT FAILURE Dr. Jeremy Nel Department of Infectious Diseases Helen Joseph Hospital VIRAL LOAD IS EVERYTHING (KINDA ) WHY DOES HIV DEVELOP (SO MUCH) RESISTANCE? Just how much
More informationHIV/AIDS Today: What you need to know when providing services to individuals with HIV/AIDS. (Part Two) Presented live August 14, 2018
HIV/AIDS Today: What you need to know when providing services to individuals with HIV/AIDS (Part Two) Presented live August 14, 2018 Welcome Back! Technical Support 800-263-6317 Mary McCarty-Arias, M.A.,
More informationWhat Women Need to Know: The HIV Treatment Guidelines for Pregnant Women
: The HIV Treatment Guidelines for Pregnant Women : The HIV Treatment Guidelines for Pregnant Women What Women Need to Know: Prepared by Elaine Gross, RN, MS, CNS-C National Pediatric & Family HIV Resource
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationManaging Transition from Pediatric to Adolescent to Adult HIV Care
Managing Transition from Pediatric to Adolescent to Adult HIV Care Allyson McKenney, MD Ilana Cohen Julie Parent Disclosure Dr. McKenney received speaker fees from Johnson & Johnson. Page 2 United Nations:
More informationPRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March
PRO 140 First self-administered antibody therapy for HIV in late-stage clinical development March 2018 Forward-Looking Statements This presentation includes forward-looking statements and forward-looking
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationModule 6: ARVs in Children
Module 6: ARVs in Children Module Objectives To review the use of ARVs in children and their impact on disease progression To provide nurses with a general understanding of the differences in ARV use in
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationFayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES
1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.
More informationHousing / Lack of Housing and HIV Prevention and Care
Housing / Lack of Housing and HIV Prevention and Care Evidence and Explanations Angela A. Aidala, PhD Columbia University Mailman School of Public Health Center for Homeless Prevention Studies WOMEN AS
More informationTransitional Care for HIV and AIDS from Adolescence to Adulthood
Transitional Care for HIV and AIDS from Adolescence to Adulthood October 2011 Featured Speaker Conflict of Interest Statement Jeffrey M. Birnbaum, MD, MPH Associate Professor of Pediatrics and Public Health,
More informationHow serious is the opiate problem in Fairfield County?
How serious is the opiate problem in Fairfield County? The Use of Opiates in Fairfield County has increased from levels in the 1990's that were barely detectable to epidemic proportions in 2010. How serious
More informationElements of the Care Continuum
Elements of the Care Continuum Michael J. Mugavero, MD, MHSc Associate Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FORMATTED: 12/09/15 Slide 3 of 38 Learning Objectives
More informationPresented at International Violence, Abuse and Trauma Conference Dr. Priscilla Dass-Brailsford Georgetown University Washington DC
The Traumatic Lives of Women Living with HIV/AIDS Presented at International Violence, Abuse and Trauma Conference 9.8.2013 Dr. Priscilla Dass-Brailsford Georgetown University Washington DC Funded By Center
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationHIV and Paediatrics in Central Europe
2nd Central and Eastern European Meeting on Viral Hepatitis and Co-Infection with HIV HIV and Paediatrics in Central Europe Mariana Mărdărescu MD PhD Consultant in Infectious Diseases Senior Doctor in
More informationThe Genetic Barrier to Resistance
The Genetic Barrier to Resistance Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Beijing, May 2013 The Genetic Barrier to Resistance The genetic
More informationBody & Soul. Research update, 25 October 2016
Body & Soul Research update, 25 October 2016 Updates from BHIVA conference on... Cure breakthrough or not? Long acting retrovirals what do they offer? When to start treatment asap post diagnosis? Media
More informationADHERENCE AND PSYCHOSOCIAL SUPPORT FOR CHILDREN AND ADOLESCENTS
www.chskenya.org ADHERENCE AND PSYCHOSOCIAL SUPPORT FOR CHILDREN AND ADOLESCENTS KPA 2018 24-04-2018 BY: MERCY WACHIRA OMONDI CHS Outline Definition of adherence Why adherence Forms of non-adherence ART
More informationWelcome to Carolinas CARE Partnership. HIV A to Z: 6/30/2015. Objectives. The Basics and Beyond. Introductions Pre-Test Expectations
Welcome to Carolinas CARE Partnership HIV A to Z: The Basics and Beyond Introductions Pre-Test Expectations Objectives Distinguish and define HIV and AIDS Brief history of the origin of HIV and AIDS Explain
More informationHIV: What Every Clinician Needs to Know ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING CONFERENCE BETTIE COPLAN MARCH 2018
HIV: What Every Clinician Needs to Know ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING CONFERENCE BETTIE COPLAN MARCH 2018 Overview Overview recent trends in HIV incidence in the U.S. HIV screening
More informationMalaysian Consensus Guidelines on Antiretroviral Therapy Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh
Malaysian Consensus Guidelines on Antiretroviral Therapy 2017 Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh Acknowledgement Table of contents Evolution of when to initiate therapy ART improves survival
More informationImmunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
More informationProgress against the HIV Epidemic: is the end in sight?
Progress against the HIV Epidemic: is the end in sight? Christine Hughes, BscPharm, PharmD, FCSHP Professor, Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Clinical Pharmacist, Northern
More informationAntiretroviral Prophylaxis and HIV Drug Resistance. John Mellors University of Pittsburgh
Antiretroviral Prophylaxis and HIV Drug Resistance John Mellors University of Pittsburgh MTN Annual 2008 Outline Two minutes on terminology Origins of HIV drug resistance Lessons learned from ART Do these
More informationPurpose Methods Demographics of patients in the study Outcome. Efficacy Adverse Event. Limitation
ANDREW LEE Purpose Methods Demographics of patients in the study Outcome Efficacy Adverse Event Limitation Dolutegravir Integrase inhibitor Plasma half life 14hours Tivicay FDA (US)- 13 August 2013 50mg
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationChronic illness and medication adherence in substance users: challenges and opportunities for research fellows FIT 2014 Cape Cod, MA
Chronic illness and medication adherence in substance users: challenges and opportunities for research fellows FIT 2014 Cape Cod, MA Julia H. Arnsten, MD, MPH Professor of Medicine, Epidemiology, and Psychiatry
More informationImmunodeficiencies HIV/AIDS
Immunodeficiencies HIV/AIDS Immunodeficiencies Due to impaired function of one or more components of the immune or inflammatory responses. Problem may be with: B cells T cells phagocytes or complement
More informationSession 1 Basic HIV Facts. Patient Navigation Intervention
Session 1 Basic HIV Facts Patient Navigation Intervention Session 1 HIV, the Viral Life Cycle & Understanding the Importance of HAART and Adherence https://www.aids.gov/hiv aids basics/just diagnosed with
More informationTunisian recommendations on ART : process and results
Second Arab Congress of Clinical Microbiology and Infectious Diseases May 24-26, 2012. Tunisian recommendations on ART : process and results M. BEN MAMOU UNAIDS Email: BenmamouM@unaids.org M. CHAKROUN
More informationAdherence in adolescents- what works? Audrey Pettifor PhD University of North Carolina at Chapel Hill
Adherence in adolescents- what works? Audrey Pettifor PhD University of North Carolina at Chapel Hill ART Coverage Rates by Age Band UNAIDS 2016 Report Zanoni and Mayer. AIDS Patient Care STDS. 2014 Mar
More informationHIV Basics for the Family Practitioner Olha Smolynets, DO
HIV BASICS FOR FAMILY PRACTITIONER, MS DISCLOSURES Dr. Smolynets has provided no disclosures. OBJECTIVES Indications for HIV screening Prevention counseling Prophylaxis: PrEP, PEP and npep Diagnosis Basic
More informationResistance Characteristics of Integrase Inhibitors
Resistance Characteristics of Integrase Inhibitors Madrid, November 2016 Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Disclaimer Presentation includes
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationEvolving HIV Treatment Paradigms What we need to know
Evolving HIV Treatment Paradigms What we need to know Benjamin Young International Association of Providers of AIDS Care Washington, DC, USA Evolving HIV Treatment Paradigms When/who to treat Better medicines
More informationThe CQUIN Learning Network
The CQUIN Learning Network Adolescents Living with HIV: National Guidelines, Minimum Package, Challenges and Priorities Swaziland Ms Nobuhle Mthethwa MOH- SWAZILAND October 24-27, 2017 Johannesburg, South
More informationPrEP for Women: HIV Prevention in Family Planning Settings
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention PrEP for Women: HIV Prevention in Family Planning Settings Dawn K. Smith, MD, MS, MPH Division of HIV/AIDS Prevention dsmith1@cdc.gov
More informationPractical Approaches of Integrating HCV into HIV Care David Hachey, Pharm.D., BCPS, AAHIVP Professor Idaho State University
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Practical Approaches of Integrating HCV into HIV Care David Hachey, Pharm.D., BCPS, AAHIVP Professor Idaho State University Presentation prepared by: David
More informationSysmex Educational Enhancement and Development No
SEED Haematology No 1 2015 Introduction to the basics of CD4 and HIV Viral Load Testing The purpose of this newsletter is to provide an introduction to the basics of the specific laboratory tests that
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationHIV/AIDS Today: What you need to know when providing services to individuals with HIV/AIDS (Part One) Presented live August 7, 2018
HIV/AIDS Today: What you need to know when providing services to individuals with HIV/AIDS (Part One) Presented live August 7, 2018 Mary McCarty-Arias, M.A., CRC More than 25 years experience training
More informationWHO recommendations for HIVDR surveillance and their application in Latin America and the Caribbean
WHO recommendations for HIVDR surveillance and their application in Latin America and the Caribbean Giovanni Ravasi Pan-American Health Organization, Brazil ravasigi@paho.org Regional Consultation on HIV
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationHow has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH
How has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH Presentation Outline Big history of global HIV epidemic Current status of HIV and the global AIDS
More informationMODULE 3 FLORIDA DEPARTMENT OF HEALTH STUDY GUIDE HIV/AIDS: 101 WEMAKETHECHANGE.COM
MODULE 3 FLORIDA DEPARTMENT OF HEALTH STUDY GUIDE HIV/AIDS: 101 WEMAKETHECHANGE.COM MODULE 3 SERVICE NEEDS FOR HIV-INFECTED INDIVIDUALS There are compelling personal and public health benefits to getting
More informationUsing anti-hiv drugs for prevention
Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment
More informationPrevention is better than cure TRANSMITTED RESISTANCE, TESTING, PITFALLS, ADHERENCE
Prevention is better than cure TRANSMITTED RESISTANCE, TESTING, PITFALLS, ADHERENCE Case 38-year-old female from Johannesburg. HIV positive. Initiated on FTC/TDF/EFV in August 2015. Along with Vitamin
More informationINH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific
INH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific Thuy Le, MD DPhil Duke University School of Medicine, USA Oxford University Clinical Research Unit Hospital
More informationDr Richard Harding. King s College London. BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Richard Harding King s College London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE 2014 Including
More informationON ATTAINING MAXIMAL AND DURABLE SUPPRESSION OF THE VIRAL LOAD. Annah M. Jeffrey, Xiaohua Xia and Ian K. Craig
ON ATTAINING MAXIMAL AND DURABLE SUPPRESSION OF THE VIRAL LOAD Annah M. Jeffrey, Xiaohua Xia and Ian K. Craig Department of Electrical, Electronic and Computer Engineering, University of Pretoria, Pretoria
More informationArizona State Office of Rural Health Webinar Series
Arizona State Office of Rural Health Webinar Series Mute your phone &/or computer microphone Time is reserved at the end for Q&A Please fill out the post-webinar survey Webinar is being recorded Recording
More informationApurba Chakraborty MBBS, MPH Dima M. Qato PharmD, MPH, PhD Professor Mark S. Dworkin MD, MPHTM The University of Illinois at Chicago
Less is More: The Impact of Lower Pill Burden on Adherence to Antiretroviral Therapy among Treatment-Naive Patients with HIV Infection in the United States Apurba Chakraborty MBBS, MPH Dima M. Qato PharmD,
More informationThe Johns Hopkins Bloomberg School of Public Health
The Johns Hopkins Bloomberg School of Public Health CONSENT FORM A / NEW RESEARCH PROJECT Title of Research Project: A Randomized Trial of HAART in Acute/Early HIV Infection Version 3.0 Principal Investigator:
More informationHIV IN PREGNANCY. Practices for Maintaining Maternal Health and Preventing Perinatal HIV Transmission. University of Tennessee Health Science Center
HIV IN PREGNANCY Practices for Maintaining Maternal Health and Preventing Perinatal HIV Transmission Nina K. Sublette, PhD, FNP University of Tennessee Health Science Center College of Nursing: Department
More informationHIV Treatment Guidelines
HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based
More informationASSESSING ADHERENCE TO COMBINATION ART IN AN URBAN PRIVATE HOSPITAL DR. EVELYN MBUGUA AGA KHAN UNIVERSITY HOSPITAL
ASSESSING ADHERENCE TO COMBINATION ART IN AN URBAN PRIVATE HOSPITAL DR. EVELYN MBUGUA AGA KHAN UNIVERSITY HOSPITAL ACKNOWLEDGMENT Supervisors: Prof. Gerald Yonga, Chairman,Dept of Medicine Dr. Reena Shah,
More informationSyndemics: Part 2. July 19, Ryan P. Westergaard, MD, PhD, MPH. Division of Infectious Diseases
Syndemics: Part 2 What Infectious Disease Providers Need to Know About Addiction Treatment July 19, 2018 Ryan P. Westergaard, MD, PhD, MPH Division of Infectious Diseases University of Wisconsin School
More informationUpdates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013
Updates on Revised Antiretroviral Treatment Guidelines 2013 Overview 27 March 2013 Introduction of Fixed Dose combination (FDC) FDCs will be available in facilities on 1 April 2013 The FDC ARV that will
More information